ViiV Healthcare Met Primary Endpoint in HIV Study
The Phase 3b Crown trial showed that Cabenuva successfully achieves viral suppression in patients with detectable HIV-1.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Do you prefer long-acting injectable medications over daily oral treatments for managing chronic health conditions?
ViiV Healthcare has announced that its Phase 3b Crown trial met its primary endpoint, demonstrating that Cabenuva provides superior viral suppression compared to daily oral antiretroviral therapy. The study focused on the direct initiation of the injectable treatment in patients with detectable virus levels.
Why it matters
The trial results address a critical evidence gap regarding the use of injectable HIV therapies for patients who are failing to maintain suppression on daily oral medication. By demonstrating efficacy in direct initiation, the study supports the expansion of long-acting treatment options.
The Crown study enrolled 326 participants across eight countries to evaluate the efficacy of the six-dose-per-year injection. This trial follows the Mocha study, which previously reported 94.4% viral suppression among adolescent participants.
The players
ViiV Healthcare
This global pharmaceutical company is a joint venture that specializes in the research and development of HIV treatments.
GSK
This multinational pharmaceutical and biotechnology corporation is the parent company that reports ViiV Healthcare's financial growth.
The details
Cabenuva, which consists of cabotegravir and rilpivirine, is administered as an injection six times per year. The study population was composed of individuals who showed no resistance to integrase inhibitors or non-nucleoside reverse transcriptase inhibitors.
Timeline
Cabenuva received its initial approval in 2021.
The drug generated 1.4 billion pounds sterling in sales during 2025.
ViiV Healthcare announced the trial results on October 6, 2026.
The Big Picture
This success extends the research foundation established by the Latitude study regarding long-term viral suppression. The findings mark a shift in treatment paradigms toward injectable, long-acting HIV medication as a standard for direct initiation.
Patients currently struggling with daily oral antiretroviral therapy may soon have a clinically validated option to switch to a twice-yearly injection. This development could simplify treatment regimens and improve long-term adherence for those with detectable HIV-1.
The takeaway
The move toward injectable treatments significantly reduces the burden of daily medication for HIV patients. Clinicians and patients should discuss the eligibility requirements for long-acting therapy as new clinical evidence emerges.
Further reading
Learn more about the latest innovations in Biotech.
Live Poll
Do you prefer long-acting injectable medications over daily oral treatments for managing chronic health conditions?
